Donor CHIP and Allogeneic HSCT Outcome
ConditionClonal Hematopoiesis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe University of Hong Kong
About this trial
Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.
Eligibility criteria
Qualifiers
Adult aged 18 year or above
Donor and recipient of allo-HSCT
voluntary provision of clinical data, and
voluntary provision of archived/remaining specimens for genetic analysis, and
Disqualifiers
None
Trial design
Treatments tested in this trial
- Next generation sequencing
Treatment groups
850 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov